+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Tumor Diagnosis & Therapeutics Market - Global Forecast 2026-2032- Product Image
Brain Tumor Diagnosis & Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Brain Tumor Diagnosis & Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011112
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Tumor Diagnosis & Therapeutics Market is projected to reach USD 3.33 Billion in 2026. It is expected to continue growing at a CAGR of 9.66%, reaching USD 5.80 Billion by 2032.

Brain tumor diagnosis and therapeutics is moving from a morphology-led specialty to an integrated precision neuro-oncology market spanning advanced MRI, PET imaging, stereotactic biopsy, molecular pathology, surgical navigation, radiotherapy planning, systemic therapy, tumor treating fields, and longitudinal monitoring.

The clinical need remains substantial. IARC GLOBOCAN 2022 estimates approximately 321,700 new brain and central nervous system cancer cases and 248,800 deaths worldwide, while U.S. CBTRUS reporting indicates more than 94,000 primary brain and CNS tumors are diagnosed annually when malignant and non-malignant tumors are combined. The 2021 WHO Classification of CNS Tumors accelerated biomarker-driven care by integrating histology with molecular features such as IDH mutation, 1p/19q co-deletion, MGMT promoter methylation, TERT promoter mutation, and H3 K27 alterations.

For diagnostics, therapeutics, and imaging stakeholders, demand is being shaped by earlier detection, surgical precision, response assessment, and therapy selection.

Transformative Shifts in the Brain Tumor Care Landscape

The landscape is shifting as brain tumor classification, treatment selection, and clinical trial design become increasingly biomarker-led. Gliomas are no longer managed by histology alone; molecular profiling now influences prognosis, eligibility for targeted therapy, and interpretation of radiographic progression.

In surgery, technologies such as intraoperative MRI, fluorescence-guided resection with 5-ALA, neuronavigation, cortical mapping, and awake craniotomy are helping neurosurgeons maximize safe resection while protecting neurological function. In radiation oncology, stereotactic radiosurgery, hypofractionation, proton therapy, and adaptive planning are enabling more personalized dose delivery.

Therapeutics are also diversifying beyond temozolomide-based regimens. FDA approvals in recent years for targeted agents in BRAF-altered pediatric low-grade glioma and IDH-mutant glioma, along with continued use of tumor treating fields in glioblastoma, show a clear movement toward molecularly segmented care. Competitive organizations are aligning diagnostics, therapeutics, and real-world evidence generation into one integrated value proposition.

Cumulative Impact of Artificial Intelligence on Neuro-Oncology

Artificial intelligence is becoming a cumulative enabler across the brain tumor pathway rather than a single-point technology. In imaging, AI-supported segmentation can help quantify enhancing tumor, edema, necrosis, and treatment-related change on MRI. In pathology, computational tools are being evaluated to support tumor grading, mitotic assessment, methylation-class prediction, and molecular triage.

The strongest near-term value is operational and clinical: faster radiology workflows, more reproducible volumetric assessment, improved radiation treatment planning, earlier identification of recurrence patterns, and more efficient trial screening. AI can also support radiomics-based risk stratification, although clinical adoption requires validation across scanners, institutions, patient demographics, and tumor subtypes.

Regulators increasingly emphasize transparency, performance monitoring, cybersecurity, and human oversight for AI-enabled medical devices. For industry leaders, success will depend on clinically validated algorithms, interoperability with PACS, EHR, pathology, and treatment planning systems, and evidence showing that AI improves decision quality without adding workflow burden.

Key Regional Insights Across Global Brain Tumor Markets

North America remains a leading region for brain tumor diagnosis and therapeutics because of dense academic cancer center networks, high MRI and neurosurgical capacity, FDA-cleared technologies, NCCN-guided care pathways, and active clinical trial enrollment. The United States anchors innovation through federal research funding, national cancer programs, university hospitals, and venture-backed medtech and biotech ecosystems, while Canada contributes through publicly funded cancer systems and collaborative neuro-oncology research.

Europe is shaped by EMA oversight, EANO guidance, national health technology assessment, and strong reference centers in the United Kingdom, Germany, France, Italy, and Spain. The region is highly influential in evidence standards, reimbursement decisions, and multinational trials. Asia-Pacific is the most demographically significant opportunity, with Japan, South Korea, Australia, China, and India expanding advanced imaging, neurosurgery, radiotherapy, and molecular testing capacity at different speeds.

Latin America, led by Brazil and Mexico, shows growing demand but uneven access to MRI, pathology, radiotherapy, and innovative oncology drugs. The Middle East is strengthening tertiary care through GCC investments in oncology hospitals and digital health infrastructure. Africa faces the greatest access constraints, including shortages of neurosurgeons, radiotherapy units, neuropathology, and molecular diagnostics, making scalable capacity-building central to market development.

Key Group Insights for Strategic Market Prioritization

ASEAN presents a mixed-access environment where Singapore, Thailand, and Malaysia offer stronger tertiary neuro-oncology capacity, while larger markets such as Indonesia, Vietnam, and the Philippines require broader investment in imaging, pathology, and specialist training. Demand is rising as health systems expand cancer coverage and private hospital networks adopt advanced MRI and radiotherapy.

The GCC is prioritizing oncology infrastructure, medical tourism, and digital transformation, making it attractive for premium diagnostics, stereotactic radiation partnerships, and AI-enabled hospital workflows. The European Union offers a large, regulated market where centralized evidence standards, medical device regulation, and cross-border cancer initiatives support harmonized adoption, although reimbursement remains country-specific.

BRICS countries represent scale, epidemiologic need, and manufacturing potential, but adoption varies widely by reimbursement, regulatory maturity, and specialist availability. G7 markets remain the core engines for brain tumor innovation, clinical trials, and premium-pricing evidence. NATO countries are relevant through resilient medical supply chains, cybersecurity standards, and overlap with advanced North American and European healthcare systems that procure high-acuity oncology technologies.

Key Country Insights Shaping Brain Tumor Market Opportunity

The United States is the largest innovation hub for brain tumor diagnostics and therapeutics, supported by FDA pathways, NCI-designated cancer centers, CBTRUS epidemiologic infrastructure, and strong clinical trial activity. Canada complements this with universal healthcare, provincial cancer agencies, and academic research networks, while Mexico and Brazil present expanding demand but face access gaps in molecular testing, radiotherapy, and high-cost therapies.

In Europe, the United Kingdom combines NHS-led pathways with genomics initiatives; Germany offers strong hospital infrastructure, imaging access, and medical technology adoption; France is influential in oncology research and reimbursement evaluation; Italy and Spain maintain major neuro-oncology centers despite regional access variation; and Russia has domestic oncology capacity but faces constraints linked to technology access and international collaboration.

In Asia-Pacific, China is rapidly expanding oncology infrastructure, domestic biopharma innovation, and clinical trial capacity. India offers high patient volume and growing private-sector neuro-oncology capability but has affordability constraints. Japan, South Korea, and Australia are advanced markets with strong imaging, surgery, regulatory systems, and research participation, making them important launch and evidence-generation countries.

Actionable Recommendations for Industry Leaders

Industry leaders should build integrated diagnostic-to-treatment pathways that connect MRI, neuropathology, molecular testing, surgical planning, radiotherapy, systemic therapy, and follow-up monitoring. Biomarker access should be treated as a commercial priority because IDH, BRAF, MGMT, 1p/19q, NTRK, and other markers increasingly influence diagnosis, prognosis, and therapy selection.

Organizations should generate region-specific evidence, including survival, functional outcomes, workflow efficiency, cost-effectiveness, and real-world utilization. AI developers must design for interoperability, explainability, bias monitoring, and post-market performance surveillance. Therapeutics developers should pair targeted therapies with companion or complementary diagnostics and prioritize adaptive trial designs for rare molecular subtypes.

Market expansion should balance premium innovation with access models, including hub-and-spoke pathology networks, cloud-supported imaging review, training partnerships, and tiered pricing strategies in emerging markets.

Research Methodology and Evidence Base

This executive summary is based on a structured secondary research methodology using publicly available and authoritative sources, including WHO and IARC GLOBOCAN cancer statistics, CBTRUS epidemiology, FDA and EMA regulatory information, NCCN and EANO clinical guidance, NIH and NCI resources, clinical trial registries, peer-reviewed medical literature, and publicly disclosed institutional information.

Insights were triangulated across epidemiology, regulatory activity, clinical adoption, reimbursement signals, technology availability, and regional healthcare capacity. Emphasis was placed on verified facts, established clinical standards, and observable market shifts rather than unsupported market-size claims.

Conclusion: Precision Neuro-Oncology Defines the Next Growth Phase

Brain tumor diagnosis and therapeutics is entering a precision-driven era defined by molecular classification, advanced imaging, targeted treatment, AI-enabled workflow optimization, and evidence-based access strategies. The burden of brain and CNS tumors remains high, and outcomes for aggressive tumors such as glioblastoma continue to create urgent demand for innovation.

The most successful organizations will not compete on single products alone. They will connect diagnostics, therapeutics, data, and care delivery into validated pathways that improve survival, preserve neurological function, and reduce unwarranted variation across regions. As neuro-oncology becomes more integrated, organizations that combine clinical credibility with scalable access models will be best positioned for sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Brain Tumor Diagnosis & Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.3.1. CART-T cell Therapy
7.3.2. Vaccine Therapy
7.4. Radiation Therapy
7.4.1. External Beam Radiation Therapy
7.4.2. Stereotactic Radiosurgery
7.4.3. Proton Therapy
7.5. Surgery
7.5.1. Open Resection
7.5.2. Minimally Invasive Surgery
7.6. Targeted Therapy
7.7. Supportive Care
8. Brain Tumor Diagnosis & Therapeutics Market, by Diagnostic Modality
8.1. Introduction
8.2. Imaging
8.2.1. Magnetic Resonance Imaging (MRI)
8.2.2. Computed Tomography (CT) Scan
8.2.3. Positron Emission Tomography (PET)
8.3. Tissue Diagnosis
8.3.1. Biopsy
8.3.2. Histopathology
8.4. Molecular Diagnostics
8.4.1. Polymerase Chain Reaction (PCR)
8.4.2. Fluorescence In Situ Hybridization (FISH)
8.4.3. Next-Generation Sequencing (NGS)
8.5. Neurological Assessment
9. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type
9.1. Introduction
9.2. Primary Brain Tumors
9.2.1. Benign
9.2.1.1. Chordomas
9.2.1.2. Glomus Jugulare
9.2.1.3. Meningiomas
9.2.1.4. Pituitary Adenomas
9.2.2. Malignant
9.2.2.1. Astrocytomas
9.2.2.2. Medulloblastomas
9.2.2.3. Glioblastomas multiforme
9.3. Secondary Brain Tumors
10. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade Type
10.1. Introduction
10.2. Grade IV
10.3. Grade III
10.4. Grade II
10.5. Grade I
11. Brain Tumor Diagnosis & Therapeutics Market, by Drug Class
11.1. Introduction
11.2. Alkylating Agents
11.3. Antimetabolites
11.4. Kinase Inhibitors
11.5. Angiogenesis Inhibitors
12. Brain Tumor Diagnosis & Therapeutics Market, by Route Of Administration
12.1. Introduction
12.2. Oral
12.3. Intravenous
12.4. Intrathecal
13. Brain Tumor Diagnosis & Therapeutics Market, by Application
13.1. Introduction
13.2. Tumor Localization
13.3. Initial Detection
13.4. Differential Diagnosis
13.5. Therapeutic Planning
13.6. Long-Term Management & Monitoring
14. Brain Tumor Diagnosis & Therapeutics Market, by End User
14.1. Introduction
14.2. Hospitals
14.3. Specialty Clinics
14.4. Ambulatory Surgical Centers
14.5. Academic & Research Institutes
15. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group
15.1. Introduction
15.2. Pediatric
15.3. Adult
15.4. Geriatric
16. Brain Tumor Diagnosis & Therapeutics Market, by Region
16.1. North America
16.2. Europe
16.3. Asia-Pacific
16.4. Latin America
16.5. Middle East
16.6. Africa
17. Brain Tumor Diagnosis & Therapeutics Market, by Group
17.1. NATO
17.2. G7
17.3. European Union
17.4. BRICS
17.5. ASEAN
17.6. GCC
18. Brain Tumor Diagnosis & Therapeutics Market, by Country
18.1. United States
18.2. China
18.3. Germany
18.4. Japan
18.5. United Kingdom
18.6. Canada
18.7. France
18.8. Mexico
18.9. South Korea
18.10. India
18.11. Brazil
18.12. Australia
18.13. Italy
18.14. Spain
18.15. Russia
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. FPNV Positioning Matrix, 2025
19.3. Market Concentration Analysis, 2025
19.3.1. Concentration Ratio (CR)
19.3.2. Herfindahl Hirschman Index (HHI)
19.4. Recent Developments & Impact Analysis, 2025
19.5. Product Portfolio Analysis, 2025
19.6. Benchmarking Analysis, 2025
20. Company Profiles
20.1. F. Hoffmann-La Roche AG
20.2. Novartis AG
20.3. Servier Group
20.4. Merck & Co. Inc.
20.5. Siemens Healthineers AG
20.6. Medtronic plc
20.7. Bayer AG
20.8. Teva Pharmaceutical Industries Ltd.
20.9. GE HealthCare Technologies Inc.
20.10. Koninklijke Philips N.V.
20.11. Laboratory Corporation of America Holdings
20.12. Elekta AB
20.13. Fujifilm Corporation
20.14. Novocure GmbH
20.15. Brainlab SE
20.16. QIAGEN N.V.
20.17. Thermo Fisher Scientific Inc.
20.18. Hikma Pharmaceuticals PLC
20.19. Sanofi S.A.
20.20. Ipsen Pharma
20.21. Danaher Corporation
20.22. Sun Pharmaceutical Industries Limited
20.23. AstraZeneca PLC
20.24. Zydus Lifesciences Limited
20.25. AbbVie Inc.
20.26. Agios Pharmaceuticals, Inc.
20.27. Amgen Inc.
20.28. Bristol-Myers Squibb Company
20.29. Carestream Health, Inc.
20.30. Eisai Co., Ltd.
20.31. Eli Lilly and Company
20.32. GlaxoSmithKline PLC
20.33. Illumina, Inc.
20.34. Johnson & Johnson Services, Inc.
20.35. Karyopharm Therapeutics Inc.
20.36. NantOmics
20.37. NeoGenomics, Inc.
20.38. Oncologica Limited
20.39. Perrigo Company
20.40. Pfizer Inc.
20.41. RemeGen Co., Ltd.
20.42. Shimadzu Corporation
20.43. Suzhou Puhe BioPharma Co., Ltd.
20.44. Takeda Pharmaceutical Company Limited
20.45. VBL Therapeutics
List of Figures
FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CART-T CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CART-T CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CART-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VACCINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VACCINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VACCINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL STEREOTACTIC RADIOSURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PROTON THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PROTON THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PROTON THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL OPEN RESECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL OPEN RESECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL OPEN RESECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MINIMALLY INVASIVE SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MINIMALLY INVASIVE SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MINIMALLY INVASIVE SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TISSUE DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TISSUE DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TISSUE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HISTOPATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEUROLOGICAL ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEUROLOGICAL ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROLOGICAL ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL BENIGN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL BENIGN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL BENIGN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CHORDOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CHORDOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CHORDOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL MENINGIOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL MENINGIOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL MENINGIOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL MALIGNANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL MALIGNANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL MALIGNANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ASTROCYTOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ASTROCYTOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ASTROCYTOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL GRADE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL GRADE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL GRADE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL GRADE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL GRADE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL GRADE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL GRADE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL GRADE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL GRADE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL GRADE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL GRADE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL GRADE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL KINASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL KINASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL ANGIOGENESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL TUMOR LOCALIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL TUMOR LOCALIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL TUMOR LOCALIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL INITIAL DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL INITIAL DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL INITIAL DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL THERAPEUTIC PLANNING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL THERAPEUTIC PLANNING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL THERAPEUTIC PLANNING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL LONG-TERM MANAGEMENT & MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL LONG-TERM MANAGEMENT & MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL LONG-TERM MANAGEMENT & MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 209. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 211. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 212. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 213. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 214. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 215. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 216. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 217. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 218. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 219. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 220. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 221. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 222. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 223. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 224. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 226. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 247. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 248. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 250. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 251. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 252. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 253. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 254. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 255. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 256. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 257. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 258. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 259. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 260. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 261. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 262. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 264. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 267. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 268. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 269. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 270. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 271. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 272. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 273. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 274. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 275. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 276. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 277. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 278. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 279. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 280. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 281. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 285. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 286. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 288. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 289. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 290. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 291. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 292. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 293. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 294. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 295. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 296. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 297. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 298. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 299. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 301. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 302. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 304. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 305. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 306. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 308. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 309. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 310. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 311. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 312. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 313. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 314. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 315. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 316. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 317. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 318. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 319. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 320. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 321. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 322. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 324. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 325. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 326. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 327. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 328. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
TABLE 329. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2017-2032 (USD MILLION)
TABLE 330. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 331. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE DIAGNOSIS, 2017-2032 (USD MILLION)
TABLE 332. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 333. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 334. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 335. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 336. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 337. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 3

Companies Mentioned

  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Servier Group
  • Merck & Co. Inc.
  • Siemens Healthineers AG
  • Medtronic plc
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips N.V.
  • Laboratory Corporation of America Holdings
  • Elekta AB
  • Fujifilm Corporation
  • Novocure GmbH
  • Brainlab SE
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Hikma Pharmaceuticals PLC
  • Sanofi S.A.
  • Ipsen Pharma
  • Danaher Corporation
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca PLC
  • Zydus Lifesciences Limited
  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Carestream Health, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • NantOmics
  • NeoGenomics, Inc.
  • Oncologica Limited
  • Perrigo Company
  • Pfizer Inc.
  • RemeGen Co., Ltd.
  • Shimadzu Corporation
  • Suzhou Puhe BioPharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBL Therapeutics

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.33 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.8 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned45

Related Topics

Related Reports

Brain Tumor Diagnosis & Treatment Market - Global Forecast 2026-2032 - Product Image

Brain Tumor Diagnosis & Treatment Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Brain Tumor Therapeutics Market - Global Forecast 2026-2032 - Product Image

Brain Tumor Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Brain Tumor Diagnosis and Treatment - Global Strategic Business Report - Product Image

Brain Tumor Diagnosis and Treatment - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From
Pediatric Brain Tumors Drug Pipeline Analysis Report 2026 - Product Image

Pediatric Brain Tumors Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Brain Tumor Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Brain Tumor Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Brain Tumor Drug Market

The Brain Tumor Drug market is a subset of the larger Brain Cancer Drug market. It is composed of drugs used to treat brain tumors, which are abnormal growths of cells in the brain. These drugs are used to reduce the size of the tumor, slow its growth, and reduce symptoms. They can be administered orally, intravenously, or intrathecally. Common drugs used to treat brain tumors include temozolomide, bevacizumab, and lomustine. The Brain Tumor Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Pfizer, Merck, and Roche. Other companies in the market include Bristol-Myers Squibb, Eli Lilly, and AstraZeneca. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.